09:12 AM EST, 02/05/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) reported six-month results from a phase 2 trial of Duravyu to treat diabetic macular edema that met primary and secondary endpoints, but its shares still slumped in premarket trading.

The company said the trial demonstrated "clinically meaningful outcomes," such as continued safety with no Duravyu-related ocular or systemic serious adverse events, and an early and sustained improvement in vision and anatomical control.

EyePoint shares were 23% lower in premarket trading